Previous 10 | Next 10 |
2023-12-05 16:05:02 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer Aclaris plummets as mid-stage trial for arthritis therapy fails ...
2023-11-18 10:30:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...
2023-11-17 15:00:53 ET More on the markets SPY: Sell The Rally - Historical Patterns Show Misplaced Optimism S&P 500: Forget The Year-End Rally The Message From 12 Post-CPI Charts The 12 least expected market outcomes of '24 - and how to trade them ...
2023-11-13 12:36:46 ET Gainers: Tenax Therapeutics ( TENX ) +310% . Tivic Health Systems ( TIVC ) +71% . Montauk Renewables ( MNTK ) +28% . Sohu.com Ltd. ( SOHU ) +24% . INVO Bioscience ( INVO ) +26% . Direct Digital Holdings...
2023-11-13 10:00:16 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
2023-11-13 08:22:15 ET Losers: Aclaris Therapeutics ( ACRS ) -85% announces top-line results from 12-Week phase 2b trial of Oral Zunsemetinib . Verve Therapeutics ( VERV ) -38% . Syntec Optics Holdings ( OPTX ) -10% . Motus GI Holdings ( MOTS ...
2023-11-13 07:56:03 ET More on Aclaris Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer Aclaris Therapeutics rises 13% on insider buy Seeking Alpha’s Quant Rating on Aclaris Therapeutics Historical earnings data for Aclaris Ther...
— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and Webcast Today at 8:00 AM ET ...
Aclaris Therapeutics Inc. (ACRS) is expected to report $-0.48 for Q3 2023
2023-11-06 07:20:03 ET More on Aclaris Therapeutics Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer Aclaris Therapeutics rises 13% on insider buy Seeking Alpha’s Quant Rating on Aclaris Therapeutics Historical earnings data for...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...